Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment.
Numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.
|Plenary and Therapeutic Sessions Include:|
|Confirmed Keynote Speech:|
|Confirmed Speakers & Chairs Include: (See the full list here)|
Presenting at the forum offers excellent opportunities to showcase your company to some of the leading global investors and corporates. It will offer you the opportunity to communicate your projected capital raising plans or simply help you in finding the right partner for your business. Presenting companies from Europe and the US will benefit from specially designed panels and keynote addresses from leading industry figures as well as access to some of the leading analysts and investors from Europe and beyond. This year, we aim to expand the audience and provide once again, opportunities for executive-level networking, deal-making and strategic partnering.
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.
To learn more about presenting, exhibition or sponsorship opportunities, please email Silvia or call +44(0)203 463 4890.
Date: 31 May, 2019
Location: Waldorf Astoria Chicago Hotel, USA
Hosted by: Sachs Association
Why: Forum brings together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment.